[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641552":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":52,"collaborators":26,"id":56,"slug":26,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":26,"enrollmentInfo":65,"targetDuration":26,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":26,"overallStatus":76,"whyStopped":26,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Lidocaine group","EXPERIMENTAL","IV lidocaine 1.5 mg\u002Fkg (diluted with 0.9% isotonic saline to a total volume of 10 ml) over 5 minutes with the start of skin incision",[13],"Drug: Lidocaine IV",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","IV 10 ml isotonic saline over the same period",[19],"Other: Saline 0.9%",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Lidocaine IV","IV lidocaine 1.5 mg\u002Fkg (diluted with 0.9% isotonic saline to a total volume of 10 ml) over 5 minutes with the start of skin incision after ensuring negative baseline headache.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Saline 0.9%","IV 10 ml isotonic saline over 5 minutes with the start of skin incision after ensuring negative baseline headache.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Osama M Rehab, MD","CONTACT","+201095210806","osamarehab@med.tanta.edu.eg",[38],{"facility":39,"status":26,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Tanta University Hospitals","Tanta","Gharbia Governorate","31527","Egypt",{"type":45,"coordinates":46},"Point",[47,48],31.00192,30.78847,{"lat":48,"lon":47},[51],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Osama Rehab","lecturer of anesthesiology, surgical intensive care and pain medicine Tanta university","100641552",false,"NCT07661758","Intravenous Lidocaine to Prevent Post-Fundal Pressure Headache During Cesarean Section","Pre-emptive Single Intravenous Lidocaine Dose to Prevent Post-Fundal Pressure Headache During Cesarean Section: The LID-HEAD Multi-center Randomized Controlled Trial","LID-HEAD","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* American Society of Anesthesiologists (ASA) Physical Status II\n* Scheduled for elective cesarean section under spinal anesthesia\n\nExclusion Criteria:\n\n* Patients declined to participate in the trial,\n* Patients with history of any type of headache, mental illness, or cerebrovascular diseases\n* Previous epidural insertion for painless labor or any other indications;\n* Patients on opioid or analgesic medications;\n* Those with pregnancy-induced hypertension or diabetic patients,\n* Allergy to lidocaine;\n* Contraindication or failure of spinal anesthesia.","FEMALE","18 Years",{"count":66,"type":67},680,"ESTIMATED","INTERVENTIONAL",[70],"PHASE3","This prospective randomized controlled multicenter study will be conducted to evaluate the effects of pre-emptive IV lidocaine dose on the incidence and severity of intraoperative headache that may occur after the extra-abdominal manual uterine fundal pressure in patients undergoing cesarean section under spinal anesthesia.",[73,74,75],"Intravenous Lidocaine","Fundal Pressure","Headache","NOT_YET_RECRUITING","2026-06-16",{"date":79,"type":80},"2026-06-22","ACTUAL",{"date":82,"type":67},"2026-07-01",{"date":84,"type":67},"2026-11-02",{"name":5,"class":6},1]